Emerging mitotic inhibitors for non-small cell carcinoma

Bibliography

• Ferlay J, Shin HR, Bray F, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Giaccone G, Smit E. Lung cancer. Cancer Chemoter Biol Response Modif 2003;21:445-83
   PubMedGoogle Scholar
• Gridelli C, Ardizzoni A, Douillard J-Y, Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010;68:319-31
   PubMed Web of Science ®Google Scholar
• Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17
   PubMed Web of Science ®Google Scholar
• Harrison MR, Holen KD, Liu G. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 2009;7(1):54-64
   PubMedGoogle Scholar
• Milross CG, Mason KA, Hunter NR, Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14
   PubMed Web of Science ®Google Scholar
• Green MR, Manikhas GM, Orlov S, Nab-paclitaxel®, a novel, Cremophor® EL-free albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17(8):1263-8
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Riely GJ, Azzoli CG, Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV nonsmall-cell lung cancer. J Clin Oncol 2008;26:639-43
   PubMed Web of Science ®Google Scholar
• Socinski MA, Manikhas GM, Stroyakovsky DL, A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:852-61
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva N, Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel and carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62
   PubMed Web of Science ®Google Scholar
• Socinski MA, Langer CJ, Okamoto I, Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24(2):314-21
   PubMed Web of Science ®Google Scholar
• Reynolds C, Barrera D, Jotte R, Phase II trial of albumin-bound paclitaxel + carboplatin + bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4(12):1-7
   PubMedGoogle Scholar
• Heist RS, Duda GD, Sahani D, In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s Suppl):abstract 7612
   Google Scholar
• Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22(10):2015-25
   PubMed Web of Science ®Google Scholar
• Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10
   PubMed Web of Science ®Google Scholar
• Larkin JM, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;18(Suppl 5):v28-34
   PubMed Web of Science ®Google Scholar
• Mani S, McDaid H, Hamilton A, Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98
   PubMed Web of Science ®Google Scholar
• Abraham J, Agrawal M, Bakke S, Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73
   PubMed Web of Science ®Google Scholar
• Zhuang S, Agrawal M, Edgerly M, A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8
   PubMed Web of Science ®Google Scholar
• Dickson N, Peck R, Wu C, Burris H. Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial. Proc Amer Soc Clin Oncol 2006;24:abstract 2040
   Google Scholar
• Vansteenkiste J, Lara PN, Le Chevalier T, Phase II clinical trial of the epothilone B analog ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55
   PubMed Web of Science ®Google Scholar
• Plummer R, Woll P, Fyfe D, A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies. Clin Cancer Res 2008;14:8288-94
   Google Scholar
• Spigel DR, Greco FA, Waterhouse DM, Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer 2012;78:70-5
   PubMed Web of Science ®Google Scholar
• Sanborn RE, Mack PC, Beckett L. Phase II trial of bevacizumab (B) and ixabepilone (Ix) for advanced non-squamous NSCLC progressive after first-line therapy. J Clin Oncol 2012;30(Suppl):abstract e 13550
   Google Scholar
• Rubin E, Rothermel J, Tesfaye F, Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120-9
   PubMed Web of Science ®Google Scholar
• Calvert P, O'Neill V, Twelves C, A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:abstract 429
   Google Scholar
• Sánchez J, Mellemgaard A, Perry M, Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial. Proc Amer Soc Clin Oncol 2006;24:abstract 7104
   Google Scholar
• Zatloukal P, Mellemgaard A, Sanchez JM, Activity of patupilone in advanced or metastatic non-small cell lung cancer: a phase II study [abstract]. Ann Oncol 2008;19(8S):296P
   Google Scholar
• Abrey L, Wen P, Govindan R, Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J Clin Oncol 2008;26(15S):abstract 2033
   Google Scholar
• Schmid P, Kiewe P, Kuehnhardt D, A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol 2005;23:abstract 2051
   Google Scholar
• Gatzemeier U, von Pawel J, Eschbach C, Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. EJC Suppl 2007;5(4):378
   Web of Science ®Google Scholar
• Chou T, Zhang X, Harris C, Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 1998;95:15798-802
   PubMed Web of Science ®Google Scholar
• Holen K, Syed S, Hannah A, Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Amer Soc Clin Oncol 2004;23:abstract 2024
   Google Scholar
• Spriggs D, Dupont J, Pezzulli A, KOS-862 (Epothilone D): phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc Amer Soc Clin Oncol 2003;22:abstract 894
   Google Scholar
• Piro L, Rosen L, Parson M, KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies. Proc Amer Soc Clin Oncol 2003;22:abstract 539
   Google Scholar
• Yee L, Lynch T, Villalona-Calero M, A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small cell lung cancer. Proc Amer Soc Clin Oncol 2005;23:abstract 7127
   Google Scholar
• Spira AI, Iannotti NO, Savin MA, A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer 2012;13(1):31-8
   PubMed Web of Science ®Google Scholar
• Scarpace SL. Eribulin mesylate (E7389) review of efficacy and tolerability in breast, pancreatic, head and neck, and non small cell lung cancer. Clin Ther 2012;34(7):1467-73
   PubMed Web of Science ®Google Scholar
• Kollareddy M, Dzubak P, Zheleva D, Hajduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152(1):27-33. 27
   PubMed Web of Science ®Google Scholar
• Dar AA, Goff LW, Majid S, Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
   PubMed Web of Science ®Google Scholar
• Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/-cells. EMBO J 2002;21:483-92
   PubMed Web of Science ®Google Scholar
• Rubin E, Shapiro G, Stein M, A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. Proc Amer Soc Clin Oncol 2006;24:abstract 3009
   Google Scholar
• Macarulla T, Rodríguez-Braun E, Tabernero J, Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 2578
   Google Scholar
• Cervantes-Ruiperez A, Elez ME, Rosello S, Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2009;15s Suppl):abstract 2565
   Google Scholar
• Lee P, Alvarez RH, Melichar B, Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2012;30(15S May 20 Suppl):3010
   Google Scholar
• Zhang J, Pan X, Astsaturov IA, Relationship of Aurora-A kinase and EGFR inhibition in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol 2011;29(Suppl):abstract e13038
   Google Scholar
• Kristeleit R, Calvert H, Arkenau H, A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 2566
   Google Scholar
• Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 2011;17:6459-66
   PubMed Web of Science ®Google Scholar
• Yuan J, Horlin A, Hock B, Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150:1165-72
   PubMed Web of Science ®Google Scholar
• Wolf G, Elez R, Doermer A, Prognostic significance of polo-like kinase (PLK) expression in non small cell lung cancer. Oncogene 1997;14:543-9
   PubMed Web of Science ®Google Scholar
• Kneisel L, Strebhardt K, Bernd A, Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29:354-8
   PubMed Web of Science ®Google Scholar
• Guan R, Tapang P, Leverson JD, Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698-704
   PubMed Web of Science ®Google Scholar
• Ellis PM, Chu QS, Leighl NB, A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(Suppl):abstract 8115
   Google Scholar
• Sebastian M, Reck M, Waller CF, The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5:1060-7
   PubMed Web of Science ®Google Scholar
• Gil T, Schöffski P, Awada A, Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl 15):abstract 3061
   Google Scholar
• Dumez H, Gombos A, Schöffski P, Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012;30(Suppl):abstract 3018
   Google Scholar
• Miki H, Setou M, Hirokawa N. Kinesin superfamily proteins (KIFs) in the mouse transcriptome. Genome Res 2003;13:1455-65
   PubMed Web of Science ®Google Scholar
• Hegde P, Cogswell J, Carrick K, Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc Amer Soc Clin Oncol 2003;22:abstract 535
   Google Scholar
• Talapatra SK, Schüttelkopf AW, Kozielski F. The structure of the ternary Eg5–ADP–ispinesib complex. Acta Cryst 2012;68:1311-19
   PubMed Web of Science ®Google Scholar
• Chu Q, Holen K, Rowinsky E, Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Amer Soc Clin Oncol 2004;22:abstract 2078
   Google Scholar
• Jones SF, Plummer ER, Burris HA, Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S June 20 Suppl):2027
   Google Scholar
• Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non- Small Cell Lung Cancer. Available from: http://www.prnewswire.com/news-releases/cytokinetics-reports-data-for-ispinesib-sb-715992-in-platinum-sensitive-non–small-cell-lung-cancer-70742202.html
   Google Scholar